Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Lunan Pharmaceutical Group Corporation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by a distinct examiner within a single art unit. This indicates that the company's current patent filings are undergoing a focused examination process. A single administrative channel can streamline the prosecution timeline by reducing the complexity of the review.
PECKHAM, RICHARD GRANT is the busiest examiner for the portfolio, managing 1 pending office action. Since there is only 1 pending office action in total, this examiner is responsible for all active prosecution for the company. The progress of this pharmaceutical application depends on the specific requirements of the assigned art unit. Success in the Biotechnology & Pharmaceuticals field will require a strategy tailored to this examiner's technical expectations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17779165 | OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17779165 | OLEAN-PHENYLACRYLAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | PECKHAM, RICHARD GRANT | 1627 | §103 | Final Rejection | — | Pending | May 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLunan Pharmaceutical Group Corporation has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Richard Grant Peckham has the most, with 1 of Lunan Pharmaceutical Group Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
